Company Announcements

GE Healthcare Life Sciences revenue was flat in the first quarter, according to GE’s conference call.

FLIR Systems named Andrew C. Teich, president of Commercial Systems, president and CEO in May, replacing Earl Lewis, who remains chairman.

QIAGEN first quarter revenues grew 2.4%, 1% organically, to $303.6 million (see IBO 4/30/13). AmniSure (see IBO 6/15/12) added 1% to sales growth, but that was mostly offset by currency headwinds. Excluding currency, Consumables and related revenues grew 4% to make up 89% of sales, and Instruments sales declined 3%. Molecular Diagnostics and Applied Testing sales grew 11% and 5% to make up 50% and 8%, respectively. Pharma and Academia sales each declined 4% to account for 18% and 24%, respectively. Sales to the Americas, Europe/Middle East/Africa and Asia-Pacific/Japan grew 2%, 4% and 3% to represent 47%, 34% and 18% of sales, respectively. Adjusted operating profit fell 7.1% to $69.8 million. In 2013, currency-neutral sales are expected to grow 5% including acquisitions.

First quarter revenue for the Test unit of Xylem’s Water Infrastructure segment declined 8% due to the timing of European project shipments in 2012, according to the company’s conference call.

Oxford Instruments restructured its Plasma Technology unit, which provides plasma etch and deposition systems, in April. The segment was redefined into three business groups, made up of multidiscipline teams.

In May, AMETEK named Richard N. (Nick) Grant, Jr., president and general manager of its Materials Analysis Division. Most recently, he served as vice president and general manager, Rosemount Temperature, at Emerson Electric.

AMETEK elected Ruby Chandy, president of Pall Industrial, to its Board in May.

MOCON formed four business units to better support its international footprint: Permeation, Package Testing, Industrial Analyzers and Microbial Detection.

For the three months ending April 30, Agilent Diagnostics and Genomics revenue grew 124.3% to $166 million (see IBO 5/15/13), but declined 3% organically. The Dako acquisition accounted for 57% of revenue and 127 percentage points of revenue growth. Excluding Dako, sales of CGH arrays, HaloPlex and TapeStation products led growth, and revenue grew 3% in Europe and 22% in Asia Pacific, excluding Japan, but declined 2% in the Americas and 27% in Japan. Orders rose 147.0% to $163 million.

In May, Harvard Bioscience appointed President David Green interim CEO, following the retirement and resignation of Chane Graziano, who resigned for personal reasons.

E. Kevin Hrusovsky, senior vice president, Life Science and Technology at PerkinElmer, resigned on May 31. He was succeeded by Jim Corbett, president of Specialty Diagnostics.